We also report how ibrutinib synergises in combination with daunorubicin, and how ibrutinib functions in part by reducing the cyto-protection provided to FLT3-ITD AML cells by bone marrow stromal cells. This evidence concerns the gene FLT3 and acute myeloid leukemia.